Clinical and Experimental Vaccine Research

  • 제12권1호
  • /
  • Pages.1-12
  • /
  • 2023
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Exploring the experience of developing COVID-19 vaccines in Iran

  • Mostafa Ghanei (Biotechnology Development Council, Vice-Presidency for Science, Technology and Knowledge-Based Economy) ;
  • Ali Mohabattalab (Department of Management and Industrial Engineering, Malek Ashtar University of Technology) ;
  • Kiarash Fartash (Institute for Science and Technology Studies, Shahid Beheshti University) ;
  • Narjes Kolahchi (Vaccine Department of Biotechnology Development Council) ;
  • Alireza Khakdaman (Department of Management, University of Tehran) ;
  • Hooman Kaghazian (Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran) ;
  • Abolfazl Bagheri (Department of Technology and Innovation Policy, National Research Institute for Science Policy)
  • 투고 : 2022.07.29
  • 심사 : 2023.01.10
  • 발행 : 2023.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Widespread public vaccination is one of the effective mechanisms to ensure the health and prevent deaths in societies. The coronavirus disease 2019 (COVID-19) vaccine is a stark instance in this regard. Vaccine development is a complex process requiring firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies. Due to the global demand for vaccines during the pandemic, the national capability to produce vaccines is critical. To this end, the current paper investigates influential factors, at the firm- and policylevel, in the COVID-19 vaccine development process in Iran. By adopting a qualitative research method and conducting 17 semi-structured interviews and analyzing policy documents, news, and reports, we extracted internal and external factors affecting the success and failure of a vaccine development project. We also discuss the characteristics of the vaccine ecosystem and the gradual maturity of policies. This paper draws lessons for vaccine development in developing countries at both firm and policy levels.

키워드

참고문헌

  1. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med 2021;27:591-600.
  2. World Health Organization. Global vaccine market report. Geneva: World Health Organization; 2020.
  3. Patel SP, Patel GS, Suthar JV. Inside the story about the research and development of COVID-19 vaccines. Clin Exp Vaccine Res 2021;10:154-70.
  4. Li L, Honda-Okubo Y, Huang Y, et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine 2021;39:5940-53.
  5. Han S. Clinical vaccine development. Clin Exp Vaccine Res 2015;4:46-53.
  6. Zhang M, Liang Y, Yu D, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 delta variant. Int J Biol Sci 2022;18:889-900.
  7. Crick JM, Crick D. Coopetition and COVID-19: collaborative business-to-business marketing strategies in a pandemic crisis. Ind Mark Manag 2020;88:206-13.
  8. Krasilnikova A. Brief overview of the currently available COVID-19 vaccines. J Clin Health Sci 2022;7:5-24.
  9. Kandimalla R, Chakraborty P, Vallamkondu J, et al. Counting on COVID-19 vaccine: insights into the current strategies, progress and future challenges. Biomedicines 2021;9:1740.
  10. Kudlay D, Svistunov A. COVID-19 vaccines: an overview of different platforms. Bioengineering (Basel) 2022;9:72.
  11. Razi Vaccine and Serum Research Institute. Razi Vaccine and Serum Research Institute website [Internet]. Karaj: Razi Vaccine and Serum Research Institute; 2022 [cited 2022 Jul 10]. Available from: https://english.rvsri.ac.ir/portal/home/?239735/Home.
  12. Maslehat S, Esmaeili Rastaghi AR, Siavashi MR, Mostafavi E. In honor of Dr. Mehdi Assmar, a distinguished researcher at the Pasteur Institute of Iran. J Res Hist Med 2021;10:81-94.
  13. Iranbio. Iranbio website [Internet]. Tehran: Iranbio; 2022 [cited 2022 Jul 10]. Available: https://iranbio.info/en.
  14. Heidarzadeh A, Moridani MA, Khoshmanesh S, Kazemi S, Hajiaghabozorgi M, Karami M. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test negative case-control study. Int J Infect Dis 2022 Dec 23 [Epub]. https://doi.org/10.1016/j.ijid.2022.12.024
  15. Mohraz M, Salehi M, Tabarsi P, et al. Safety and immunogenicity of an inactivated virus particle vaccine for SARSCoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open 2022;12:e056872.
  16. Majidpour M, Saber A, Elahi S, Shayan A, Khorasani SM. Technological catch-up in the biopharmaceutical sector: evidence from Iran. Technol Soc 2021;67:101695.
  17. Tabarsi P, Anjidani N, Shahpari R, et al. Safety and immunogenicity of SpikoGen, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clin Microbiol Infect 2022;28:1263-71.
  18. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A narrative review of COVID-19 vaccines. Vaccines (Basel) 2021;10:62.
  19. Ghasemi S, Naderi Saffar K, Ebrahimi F, et al. Development of inactivated FAKHRAVAC vaccine against SARSCoV-2 virus: preclinical study in animal models. Vaccines (Basel) 2021;9:1271.
  20. Perez C. Technological revolutions and financial capital. Cheltenham: Edward Elgar Publishing; 2003.
  21. Tasnim News Agency. Medical news, financial support of Iranian COVID-19 vaccine development [Internet]. Tehran: Tasnim News Agency; 2022 [cited 2022 Jul 10]. Available from: https://tn.ai/2599659.
  22. World Health Organization. Increasing access to vaccines through technology transfer and local production. Geneva: World Health Organization; 2011.
  23. Al-Mistarehi AH, Kheirallah KA, Yassin A, et al. Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country. Clin Exp Vaccine Res 2021;10:171-82.